Health Affairs Blog

Dr. Peter Hotez and Remko van Leeuwen discuss the importance of a hookworm vaccine, and the role of the HOOKVAC Consortium in delivering it. 

"In response to this threat, the Sabin Vaccine Institute Product Development Partnership developed the first-ever human hookworm vaccine, now being advanced through a European consortium of partners—HOOKVAC—based at the Amsterdam Institute for Global Health and Development, and funded by the European Union, in addition to the Dutch Ministry of Foreign Affairs, the Bill & Melinda Gates Foundation, and the Michelson Medical Research Foundation. Through HOOKVAC, the vaccine is now in clinical testing in Gabon where more than one in four people are infected with hookworms.

HOOKVAC represents a critical enabling mechanism to advance the testing of the human hookworm vaccine. Otherwise, it is unlikely a major or multinational pharmaceutical company would initially undertake such a project, given the fact that hookworm mostly strikes only the poorest of the poor in developing countries."